F. Binder-foucard, A. Belot, P. Delafosse, L. Remontet, A. Woronoff et al., Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1 -Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire

L. Daubisse-marliac, P. Delafosse, J. Boitard, F. Poncet, P. Grosclaude et al., Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries, Annals of Oncology, vol.22, issue.2, pp.329-363, 2011.
DOI : 10.1093/annonc/mdq396

H. Weedon-fekjaer, K. Bakken, L. Vatten, and S. Tretli, Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use, BMJ, vol.344, issue.jan30 1, p.299, 2012.
DOI : 10.1136/bmj.e299

M. Gorza, E. Salines, and J. Bloch, Dépistage organisé du cancer du sein -Évaluation épidémiologique -Données 2005. Saint-Maurice (Fra): Institut de veille sanitaire, p.366, 2008.

B. Yankaskas, C. Klabunde, R. Ancelle-park, G. Renner, H. Wang et al., International comparison of performance measures for screening mammography: can it be done?, Journal of Medical Screening, vol.11, issue.4, pp.187-93, 2004.
DOI : 10.1258/0969141042467430

N. Wolpert, E. Warner, M. Seminsky, A. Futreal, and S. Narod, Prevalence of BRCA1 and BRCA2 Mutations in Male Breast Cancer Patients in Canada, Clinical Breast Cancer, vol.1, issue.1, pp.57-63, 2000.
DOI : 10.3816/CBC.2000.n.005

J. Kelsey and L. Bernstein, Epidemiology and Prevention of Breast Cancer, Annual Review of Public Health, vol.17, issue.1, pp.47-67, 1996.
DOI : 10.1146/annurev.pu.17.050196.000403

A. Nkondjock and P. Ghadirian, Facteurs de risque du cancer du sein, m??decine/sciences, vol.21, issue.2, pp.175-80, 2005.
DOI : 10.1051/medsci/2005212175

V. Beral, M. Women-study, and . Collaborators, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-446, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

P. Layde, L. Webster, A. Baughman, P. Wingo, G. Rubin et al., The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer, Journal of Clinical Epidemiology, vol.42, issue.10, pp.963-73, 1989.
DOI : 10.1016/0895-4356(89)90161-3

M. Hinkula, E. Pukkala, P. Kyyrönen, and A. Kauppila, Grand multiparity and the risk of breast cancer: population-based study in Finland, Cancer Causes and Control, vol.12, issue.6, pp.491-500, 2001.
DOI : 10.1023/A:1011253527605

J. Russo, Y. Hu, X. Yang, and I. Russo, Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer, JNCI Monographs, vol.2000, issue.27, pp.17-37, 2000.
DOI : 10.1093/oxfordjournals.jncimonographs.a024241

L. Lostumbo, N. Carbine, and J. Wallace, Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, issue.11, p.2748, 2010.

D. Ford, D. Easton, M. Stratton, S. Narod, D. Goldgar et al., Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families, The American Journal of Human Genetics, vol.62, issue.3, pp.676-89, 1998.
DOI : 10.1086/301749

T. Key, P. Verkasalo, and E. Banks, Epidemiology of breast cancer, The Lancet Oncology, vol.2, issue.3, pp.133-173, 2001.
DOI : 10.1016/S1470-2045(00)00254-0

M. Kirschner, E. Samojlik, M. Drejka, E. Szmal, G. Schneider et al., Lower Body Obesity*, The Journal of Clinical Endocrinology & Metabolism, vol.70, issue.2, pp.473-482, 1990.
DOI : 10.1210/jcem-70-2-473

H. Autorité and D. Santé, Institut National du Cancer La prise en charge du cancer du sein, 2010.

K. Armstrong, E. Handorf, J. Chen, and M. Demeter, Breast Cancer Risk Prediction and Mammography Biopsy Decisions, American Journal of Preventive Medicine, vol.44, issue.1, pp.15-22, 2013.
DOI : 10.1016/j.amepre.2012.10.002

R. Weinberg, The Biology of Cancer, Garland Science, vol.876, 2007.

J. Saglier, P. Beuzeboc, A. Pommeyrol, and A. Toledano, Cancer du sein: questions et réponses au quotidien, 2009.

N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18, JNCI Monographs, vol.2001, issue.30, pp.96-102, 2001.
DOI : 10.1093/oxfordjournals.jncimonographs.a003469

J. Ruiterkamp and M. Ernst, The role of surgery in metastatic breast cancer, European Journal of Cancer, vol.47, pp.6-22, 1990.
DOI : 10.1016/S0959-8049(11)70142-3

A. Nationale-d, Accréditation et d'Evaluation en Santé. La technique du ganglion sentinelle dans le cancer du sein

S. Zurrida, A. Morabito, V. Galimberti, A. Luini, M. Greco et al., Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer., International Journal of Oncology, vol.15, issue.3, pp.475-80, 1999.
DOI : 10.3892/ijo.15.3.475

J. Van-de-steene, G. Soete, and G. Storme, Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link, Radiotherapy and Oncology, vol.55, issue.3, pp.263-72, 2000.
DOI : 10.1016/S0167-8140(00)00204-8

S. Sommer and S. Fuqua, Estrogen receptor and breast cancer, Seminars in Cancer Biology, vol.11, issue.5, pp.339-52, 2001.
DOI : 10.1006/scbi.2001.0389

L. Huiart, V. Bardou, B. Puig, and D. Maraninchi, Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women, Bull Cancer (Paris). avr, vol.93, issue.4, pp.391-400, 2006.

C. Osborne, Tamoxifen in the Treatment of Breast Cancer, New England Journal of Medicine, vol.339, issue.22, pp.1609-1627, 1998.
DOI : 10.1056/NEJM199811263392207

L. Mauriac, A. Keshaviah, M. Debled, H. Mouridsen, J. Forbes et al., Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Annals of Oncology, vol.18, issue.5, pp.859-67, 2007.
DOI : 10.1093/annonc/mdm001

D. Mauri, N. Pavlidis, N. Polyzos, and J. Ioannidis, Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis, JNCI: Journal of the National Cancer Institute, vol.98, issue.18
DOI : 10.1093/jnci/djj357

C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris et al., Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-745, 2002.
DOI : 10.1200/JCO.20.3.719

A. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss et al., Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840, Journal of Clinical Oncology, vol.26, issue.10, pp.1642-1651, 2008.
DOI : 10.1200/JCO.2007.11.6699

Y. Yarden and M. Sliwkowski, Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-164, 2001.
DOI : 10.1038/35052073

E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer et al., Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-84, 2005.
DOI : 10.1056/NEJMoa052122

O. Scully, B. Bay, G. Yip, and Y. Yu, Breast cancer metastasis, Cancer Genomics Proteomics. oct, vol.9, issue.5, pp.311-331, 2012.

B. Weigelt, J. Peterse, . Van-'t, and L. Veer, Breast cancer metastasis: markers and models, Nature Reviews Cancer, vol.945, issue.8, pp.591-602, 2005.
DOI : 10.1038/nm0803-999b

P. Greenberg, G. Hortobagyi, T. Smith, L. Ziegler, D. Frye et al., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer., Journal of Clinical Oncology, vol.14, issue.8, pp.2197-205, 1996.
DOI : 10.1200/JCO.1996.14.8.2197

M. Stockler, N. Wilcken, D. Ghersi, and R. Simes, Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer, Cancer Treatment Reviews, vol.26, issue.3, pp.151-68, 2000.
DOI : 10.1053/ctrv.1999.0161

A. Gennari, P. Conte, R. Rosso, C. Orlandini, and P. Bruzzi, Survival of metastatic breast carcinoma patients over a 20-year period, Cancer, vol.26, issue.8, pp.1742-50, 2005.
DOI : 10.1002/14651858.CD003366

A. Niwi?ska, M. Murawska, and K. Pogoda, Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT), Annals of Oncology, vol.21, issue.5, pp.942-950, 2010.
DOI : 10.1093/annonc/mdp407

S. Aebi, T. Davidson, G. Gruber, F. Cardoso, . Esmo-guidelines-working et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol ESMO. sept, vol.22, issue.6, pp.12-24, 2011.

J. Gligorov, Trastuzumab après progression chez les patientes HER2+ ayant un cancer du sein avancé : résultats de l'étude GBG-26/BIG 03-05, Lett Cancérologue. juin, vol.XVIII, issue.6, 2009.

C. Willett, Y. Boucher, E. Di-tomaso, D. Duda, L. Munn et al., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nature Medicine, vol.10, issue.2, pp.145-152, 2004.
DOI : 10.1038/nm988

. Loi, de financement de la sécurité sociale pour, 1199.

. Insee, Santé -Dépenses de santé [Internet], Disponible sur, 2014.

M. Lidgren, N. Wilking, B. Jönsson, and C. Rehnberg, Resource use and costs associated with different states of breast cancer, International Journal of Technology Assessment in Health Care, vol.86, issue.02, pp.223-254, 2000.
DOI : 10.1007/978-1-4757-6822-0

L. Dahlberg, J. Lundkvist, and H. Lindman, Health care costs for treatment of disseminated breast cancer, European Journal of Cancer, vol.45, issue.11, pp.1987-1991, 2009.
DOI : 10.1016/j.ejca.2009.03.023

B. Poncet, C. Colin, T. Bachelot, I. Jaisson-hot, L. Derain et al., Treatment of Metastatic Breast Cancer, American Journal of Clinical Oncology, vol.32, issue.4, pp.369-74, 2009.
DOI : 10.1097/COC.0b013e31818c08d3

S. Baffert, P. Cottu, Y. Kirova, and F. Mercier, Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study, BMC Health Services Research, vol.108, issue.2, p.456, 2013.
DOI : 10.1007/s10549-007-9601-0

T. Guesmina, . Robain, . Perol, and . Favier, Plateforme de donnée de vie réelle ESME. Constitution d'une liste de sélection exhaustive multi-source.Revue d'épidémiologie et de, pp.117-136, 2016.

L. Benjamin, F. Cotte, F. Mercier, A. Vainchtock, G. Vidal-trecan et al., Burden of breast cancer with brain metastasis: a French national hospital database analysis, Journal of Medical Economics, vol.15, issue.3, pp.493-499
DOI : 10.3111/13696998.2012.662924

C. Perez-ellis, A. Goncalves, J. Jacquemier, M. Marty, V. Girre et al., Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer, American Journal of Clinical Oncology, vol.32, issue.5, pp.492-498, 2009.
DOI : 10.1097/COC.0b013e3181931277

E. Pelletier, B. Shim, S. Goodman, and M. Amonkar, Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis, Breast Cancer Research and Treatment, vol.27, issue.12, pp.297-305, 2008.
DOI : 10.1007/s10549-007-9601-0